COVID-19’s impact on quality of life (QoL) has been studied; however, data on the effects of long COVID on QoL and mental disability remain limited. This study aimed to investigate whether long COVID is associated with decreased QoL and increased mental disability. We analyzed data from adults (≥18 years) in the 2022 Medical Expenditure Panel Survey (MEPS). Physical and mental QoL were assessed using the Veterans RAND 12-Item Health Survey, while mental disability was measured with the Kessler Index. Long COVID was defined as experiencing COVID-related symptoms for over 3 months. To account for skewness in the outcome variables, the study employed survey-weighted generalized linear regression with a log link and gamma distribution. The analysis included 153,330,408 subjects (unweighted n = 10,975). The average age of those with and without long COVID was similar (51 vs. 52 years, p = 0.46). Subjects with long COVID had a 3% lower physical QoL (β = −0.03, p = 0.02), a 4% lower mental QoL (β = −0.04, p < 0.01), and a 26% higher mental disability score (β = 0.26, p < 0.01) compared to those without long COVID. These findings highlight the urgent need for targeted strategies to address long COVID and support patients in recovering their pre-COVID QoL and mental health.

Long-term care (LTC) refers to care and support services that are required by individuals who lack the ability to perform important daily routines and may be dependent on others for personal, social and medical needs over a sustained period of time. LTC may be broadly categorized into formal and informal care, where formal care is provided by professionals who are compensated to provide these services and informal care captures the care services provided without compensation by family members, friends, or other unpaid individuals. In this narrative review, we identify and synthesize evidence to evaluate the cost of long-term care while balancing the needs of caregivers. We searched Embase and EconLit for studies published from 2010 to November 2023. Our search strategy used a combination of keywords such as 'long-term care,' 'caregiver burden,' 'caregiver support,' 'cost of care,' and 'caregiver wellbeing.' We include both formal and informal LTC, as well as predictors of caregiver wellbeing. The review highlights the global variability in LTC costs and the significant burden on caregivers, emphasizing the need for policy interventions and comprehensive insurance schemes. Future research should focus on standardized assessment tools, intervention effectiveness, and integrating caregiver support into healthcare models, ensuring holistic and sustainable LTC solutions.

Background: Access to pharmacy services is a critical determinant of health care equity, as it directly impacts medication adherence, chronic disease management, and overall health outcomes. Despite the important role of community pharmacies in the United States, disparities in access persist, particularly among rural, minority, and low-income populations. However, there is no consensus on how pharmacy access should be defined or measured, and how these definitions relate to health outcomes. Objective: This review evaluates how pharmacy access is defined and measured in US-based studies and examines its implications on health outcomes, quality of care, and health care costs. Methods: We conducted a scoping review of US-based studies published over the past 20 years, identifying patterns in definitions and measurements of pharmacy access, as well as associated health outcomes. The review followed Arksey and O’Malley’s framework and PRISMA-ScR guidelines. Results: Sixteen studies met the inclusion criteria, most of which used cross-sectional designs. Definitions of pharmacy access varied, with metrics including distance to the nearest pharmacy, pharmacy density, and the concept of pharmacy deserts. Limited pharmacy access was associated with lower medication adherence, poorer chronic disease management, increased health care costs, and higher hospitalization rates. Conclusions: Efforts to improve pharmacy access should focus on standardizing measurement approaches and implementing targeted interventions to sustain pharmacies in underserved areas. These strategies have the potential to enhance medication adherence, reduce health care costs, and address health disparities across vulnerable communities.

Long COVID increases healthcare utilization, yet differences in healthcare spending patterns between individuals with and without long COVID remain poorly characterized, especially at the national level. To evaluate differences in healthcare expenditures among U.S. adults with and without long COVID using nationally representative data. This cross-sectional study analyzed data from the 2022 Medical Expenditure Panel Survey (MEPS), including 16 762 unweighted adults (weighted population: 239 915 159). Healthcare spending outcomes included total expenditures and specific categories including office-based care, outpatient services, emergency room visits, hospital admissions, home healthcare, and prescription medications. A survey-weighted generalized linear model (GLM) with a log link and gamma distribution was used to estimate adjusted differences in expenditures between groups. Individuals with long COVID had significantly higher total healthcare expenditures (mean $11 567; SD $25 334) compared to those without long COVID ($7448; SD $21 734, P < .01). After adjusting for demographic characteristics, insurance status, chronic conditions, and other potential confounders, individuals with long COVID incurred 40% higher total expenditures (β = 1.40, P = .01). Expenditures were significantly elevated for office-based visits (35% higher; β = 1.35, P = .02) and outpatient services (118% higher; β = 2.18, P < .01). No significant differences were found in emergency room, hospital admissions, or dental care expenditures. Long COVID imposes a substantial financial burden on individuals and healthcare systems, primarily through increased outpatient and office-based service utilization. Understanding these spending patterns can help inform policy decisions, optimize healthcare resource allocation, and guide targeted interventions to manage long COVID more effectively.

Introduction: Rapid increased utilization of GLP-1s by US patients has raised safety concerns, in addition to challenges related to supply shortfalls starting in March 2022. Methods: We analyzed publicly available FDA Adverse Event Reporting System (FAERS) data from January 2015 through December 2024 to describe adverse events where GLP-1s were the primary suspect and compared them with events involving injectable insulin products. Results: Among the 112 532 reports analyzed, GLP-1s were associated with a higher share of administration-related reactions (63%) compared to insulin (39%). Reports of dosing issues and administration errors increased for GLP-1s beginning in Q4 2022 and rose further in 2023 and 2024, patterns not seen for insulin. Increases coincided temporally with the period of national GLP-1 shortages. Increases in reporting volume may reflect increased utilization rather than increased risk as FAERS lacks exposure denominators. Conclusion: The shift toward administration-related and dosing-related reports underscores the importance of patient and provider education and continued regulatory attention to the use of these drugs even as supply shortfalls resolve. Ongoing post-marketing surveillance remains essential to monitor safety signals.

Objectives: Evidence suggests that COVID-19 infection contributes to elevated risks of psychiatric disorders, including depression and anxiety, however, this association remains underexplored. This study aimed to examine the incidence of depression and anxiety in individuals with COVID-19 compared to those without any infection. Method: Using the Utah All Payers Claims Database (2019 to 2021), we examined adult patients with continuous insurance enrollment. Individuals with pre-existing depression or anxiety were excluded. COVID-19 infection in 2020 was identified using diagnostic and procedural codes. The Least Absolute Shrinkage and Selection Operator (LASSO) method was applied to select covariates, followed by entropy balancing to adjust for baseline differences. Weighted logistic regression models were used to estimate the association between COVID-19 infection and incident mental health diagnoses in 2021. Results: Among 356,985 adults included in the final analytic sample for depression analysis, 37.6 percent had a documented COVID-19 infection in 2020. Individuals with prior infection had significantly higher odds of receiving a depression diagnosis in 2021 compared to those without infection (OR = 1.48, p < 0.01). A similar pattern was observed for anxiety: among 371,491 adults, 38.1 percent had a COVID-19 infection, and infected individuals had 46 percent greater odds of receiving an anxiety diagnosis (OR = 1.46, p < 0.01), after adjusting for demographic and clinical characteristics. Conclusions: This study highlights the elevated risk of depression and anxiety among patients who had been infected with COVID-19, emphasizing the importance of addressing the mental health needs of individuals affected by the virus.